<DOC>
	<DOCNO>NCT01951209</DOCNO>
	<brief_summary>Hepatitis C lead cause chronic liver disease cirrhosis United States veteran . Cirrhosis associate impaired antibody response increase risk bacterial infection . We recently identify cirrhosis associate abnormality memory B-cells , cell make antibody help protect bacterial infection . We identify chemical associate gut bacteria might play role cause B-cell abnormality . It well know gut bacteria increase access blood individual cirrhosis , process call bacterial translocation . We hypothesize reduce bacteria count gut use poorly-absorbed antibiotic ( also know selective gut decontamination ) partially reverse loss memory B-cells cirrhosis reduce bacterial translocation .</brief_summary>
	<brief_title>Pilot Study Of The Effect Of Rifaximin On B-Cell Dysregulation In Cirrhosis</brief_title>
	<detailed_description>We intend enroll 18 patient cirrhosis hepatic encephalopathy prospectively evaluate impact rifaximin B-cell phenotype function . We plan employ randomize , double-masked , prospective crossover design minimize bias . Subjects randomize receive either rifaximin SSD 80mg match placebo daily 12 week cross opposite therapy 12 week . Serum lymphocytes collect baseline every 4 week vitro assessment marker gut microbial translocation B-cell assay . Stool collect baseline every 12 week future evaluation change gut microbiome .</detailed_description>
	<mesh_term>Hepatitis</mesh_term>
	<mesh_term>Hepatitis A</mesh_term>
	<mesh_term>Hepatitis C</mesh_term>
	<mesh_term>Hepatitis , Chronic</mesh_term>
	<mesh_term>Hepatitis C , Chronic</mesh_term>
	<mesh_term>Fibrosis</mesh_term>
	<mesh_term>Liver Cirrhosis</mesh_term>
	<mesh_term>Rifaximin</mesh_term>
	<mesh_term>Rifamycins</mesh_term>
	<criteria>Current prior chronic Hepatitis C infection document detectable HCV RNA prior 5 year ChildTurcottePugh stage A5B8 . Cirrhosis diagnosis may base either histological criterion ( previous liver biopsy show F4/4 F56/6 fibrosis ) clinical criterion ( nodular liver abdominal imaging , splenomegaly , thrombocytopenia , spider telangiectasias , palmar erythema , ascites , varix ) . Platelet count &lt; 175,000/ul Subject capable give informed consent Active alcohol use &gt; 20g/d Current plan ( within follow 6 month ) antiviral therapy hepatitis C HIV coinfection Diagnosis overt hepatic encephalopathy Current lactulose use Exposure rifaximin , rifampin rifabutin within 12 month History C. difficile colitis History adverse drug reaction sensitivity rifaximin , rifampin rifabutin inactive component rifaximin Pregnancy Anemia hemoglobin &lt; 10g/dl hematocrit &lt; 30 % Chronic kidney disease creatinine &gt; 2.1mg/dl Total bilirubin &gt; 3.0g/dl Active nonhepatic medical condition congestive heart failure , chronic lung disease require oxygen , coronary artery disease unstable angina Requirement chronic immunosuppressive therapy corticosteroid , cyclophosphamide , azathioprine , TNFalpha antagonists Chronic autoimmune disease systemic lupus erythematosus rheumatoid arthritis Postliver transplantation status anticipate liver transplantation within 6 month . Systemic antimicrobial exposure within 30 day plan Visit 1</criteria>
	<gender>All</gender>
	<minimum_age>18 Years</minimum_age>
	<maximum_age>70 Years</maximum_age>
	<verification_date>September 2016</verification_date>
	<keyword>Human</keyword>
	<keyword>Hepatitis C</keyword>
	<keyword>Cirrhosis</keyword>
	<keyword>B-cell</keyword>
	<keyword>Rifaximin</keyword>
</DOC>